GlassScriptPhysician profile
Gideon L King
NPI 1548255367
$6,747.94
in general payments reported to CMS, 2019-2025
53 companies · $646 in 2025
The $646 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,850 · 2020: $1,296 · 2021: $1,262 · 2022: $321 · 2023: $665 · 2024: $708 · 2025: $646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $918.39 | 2019-2025 | |
| Novo Nordisk INC | $662.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $503.71 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $497.51 | 2019-2021 | |
| Pfizer INC. | $388.77 | 2019-2025 | |
| Amarin Pharma, INC. | $367.03 | 2019-2022 | |
| Lilly USA, LLC | $305.30 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.14 | 2019-2021 | |
| Amgen INC. | $243.81 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Glaxosmithkline, LLC. | $227.78 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $201.91 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.19 | 2019-2024 | Jardiance |
| Allergan, INC. | $180.99 | 2019-2020 | |
| Abbott Laboratories | $163.59 | 2021-2024 | Freestyle Libre 3 |
| Mannkind Corporation | $122.60 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gideon King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.